Almirall to Update R&D Pipeline at 2026 J.P. Morgan Healthcare Conference
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 2d ago
0mins
Source: Businesswire
- R&D Pipeline Progress: Almirall is conducting three Phase II studies targeting high unmet medical needs in skin diseases, with plans to initiate three additional proof-of-concept studies in 2026, showcasing the company's ongoing innovation in medical dermatology.
- Strong Market Performance: The company anticipates a double-digit CAGR in net sales by 2030, reinforcing its leadership in medical dermatology, particularly following the successful launches of its biologics, with expected peak sales of over €450 million for Ebglyss® and over €300 million for Ilumetri®.
- New Product Development: Almirall plans to advance a bispecific antibody targeting atopic dermatitis into Phase I clinical trials in the first half of 2026, further enriching its biologics portfolio to meet urgent patient needs for new therapies.
- Industry Collaboration and Investment: The company collaborates with leading global experts and continues to invest in R&D infrastructure, committed to addressing unmet needs in dermatology, demonstrating its long-term vision and strategic commitment in the field.
Analyst Views on ALM
Wall Street analysts forecast ALM stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ALM is 11.96 USD with a low forecast of 11.96 USD and a high forecast of 11.96 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
2 Analyst Rating
2 Buy
0 Hold
0 Sell
Moderate Buy
Current: 9.000
Low
11.96
Averages
11.96
High
11.96
Current: 9.000
Low
11.96
Averages
11.96
High
11.96
About ALM
Almonty Industries Inc. is a diversified and global producer of tungsten concentrate. The Company is engaged in mining, processing and shipping tungsten concentrate from its Panasqueira Mine in Portugal. It also has a significant molybdenum resource on a separate property adjacent to the tungsten orebody at the Sangdong Mine. Its additional development projects include the Valtreixal Project in northwestern Spain and Los Santos Mine in western Spain. The Panasqueira Mine is located in Covilha, Castelo Branco, Portugal. The Sangdong Mine is located at Sangdong in the south-eastern Korean Peninsula, approximately 170 km east-southeast of Seoul, South Korea. The Valtreixal Mine is a potential open pit operation, and is located in the northwest part of the Zamora province, in the Castilla de Leon region of Spain. It also operates Woulfe, whose properties are located in Gangwon Province, Republic of Korea, and whose operations relate primarily to the development of the Sangdong Project.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
